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ABSTRACT
In this paper, we propose a mean score equation-based approach to estimate the the
volume under the receiving operating characteristic (ROC) surface (VUS) of a diagnos-
tic test, under nonignorable (NI) verification bias. The proposed approach involves a
parametric regression model for the verification process, which accommodates for possi-
ble NI missingness in the disease status of sample subjects, and may use instrumental
variables, which help avoid possible identifiability problems. In order to solve the mean
score equation derived by the chosen verification model, we preliminarily need to esti-
mate the parameters of a model for the disease process, but its specification is required
only for verified subjects under study. Then, by using the estimated verification and dis-
ease probabilities, we obtain four verification bias-corrected VUS estimators, which are
alternative to those recently proposed by To Duc et al. (2019), based on a full likelihood
approach. Consistency and asymptotic normality of the new estimators are established.
Simulation experiments are conducted to evaluate their finite sample performances, and
an application to a dataset from a research on epithelial ovarian cancer is presented.
Key words: Diagnostic test; Instrumental variable; Mean score equation; Nonignorable missing
data mechanism; ROC analysis; Verification bias.
1 Introduction and background
The evaluation of the accuracy of diagnostic tests (or biomarkers) is an increasingly relevant
issue in modern medicine. Usually, this issue is solved by means of a receiver operating
characteristic (ROC) analysis. In particular, the volume under the ROC surface (VUS) is
often used for measuring the overall accuracy of a diagnostic test when the possible disease
status belongs to one of three ordered categories. Under correct ordering, values of VUS vary
from 1/6, suggesting that the test is no better than chance alone, to 1, that implies a perfect
test, i.e. a test that perfectly discriminates among the three categories (Scurfield, 1996).
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In medical studies, the VUS of a new test is typically estimated through a sample of
measurements obtained by some suitable sample of patients, for which the true disease status
is assessed by means of a gold standard (GS) test. However, in many cases, due to the
expensiveness and/or invasiveness of the GS test, only a subset of patients undergoes disease
verification. In such situations, statistical inference based only on verified subjects is typically
biased. This bias is known as verification bias.
In order to correct for verification bias, the researchers must formulate some assumptions
about the selection mechanism for the disease verification. When the decision to send a
subject to verification may be directly based on the presumed subject’s disease status, or,
more generally, the selection mechanism may depend on some unobserved covariates related
to disease, the missing data mechanism is called nonignorable (NI).
Generally speaking, NI data missingness is a challenge for inference, and, specifically, the
issue of correcting for NI verification bias in ROC surface analysis is still scarcely considered
in the statistical literature. To the best of our knowledge, only Zhang and Alonzo (2018) and
To Duc et al. (2019) gave a contribution in this direction. In particular, To Duc et al. (2019)
extended the model discussed in Liu and Zhou (2010) to match the case of three-category dis-
ease status, and proposed a likelihood-based approach to derive four bias–corrected estimators
of the VUS, namely, full imputation (FI), mean score imputation (MSI), inverse probability
weighting (IPW) and pseudo doubly robust (PDR) estimators.
Suppose we need to evaluate the predictive ability of a new continuous diagnostic test in
a context where the disease status of a patient can be described by three ordered categories,
“non–diseased”, “intermediate” and “diseased”, say. Consider a sample of n subjects and let
T , D and A denote the test result, the disease status and a vector of covariates for each subject,
respectively. Hereafter, we assume, without loss of generality, that test values are positively
associated with the severity degree of the disease. The disease status D can be modeled as
a trinomial random vector D = (D1, D2, D3)>, such that Dk is a Bernoulli random variable
having mean θk = Pr(Dk = 1) where θ1 + θ2 + θ3 = 1. Hence, θk represents the probability
that a generic subject, classified according to its disease status, belong to the class k. The
accuracy of T is measured by its VUS, which is defined as
µ =
E (Ii`rD1iD2`D3r)
E (D1iD2`D3r)
, (1.1)
where the indices i, `, r refer to three different subjects, Ii`r = I(Ti < T` < Tr) +
1
2 I(Ti <
T` = Tr) +
1
2 I(Ti = T` < Tr) +
1
6 I(Ti = T` = Tr) and I(·) is the indicator function (Nakas
and Yiannoutsos, 2004). When the disease status D is available for all subjects, a natural
nonparametric estimator of µ is given by
µ̂NP =
n∑
i=1
n∑
`=1,` 6=i
n∑
r=1
r 6=`,r 6=i
Ii`rD1iD2`D3r
n∑
i=1
n∑
`=1,` 6=i
n∑
r=1
r 6=`,r 6=i
D1iD2`D3r
. (1.2)
Suppose now that the disease status D is missing for a subset of patients in the study. Let
Vi be the verification status for the i-th subject in study, that is Vi = 1 if Di is observed and
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Vi = 0 otherwise. To account for a possible nonignorable missing data mechanism for the
disease status, To Duc et al. (2019) considered the verification model
pi = Pr(V = 1|T,A, D1, D2) =
exp
(
β0 + β1T + β
>
2 A+ λ1D1 + λ2D2
)
1 + exp
(
β0 + β1T + β
>
2 A+ λ1D1 + λ2D2
) , (1.3)
where the parameters λ1 and λ2 describe the type of missingness mechanism. In particular,
the missing data mechanism is ignorable (MAR) if λ1 = λ2 = 0; NI, otherwise. Following
Liu and Zhou (2010), to estimate the parameter φ = (β0, β1,β
>
2 , λ1, λ2)
> in the verification
model (1.3), To Duc et al. (2019) proposed to use a likelihood-based approach. Specifically,
the authors assumed that the disease process follows a multinomial logistic model for the
whole sample, i.e.,
ρk =
exp
(
η
(k)
0 + η
(k)
1 T +A
>η(k)2
)
1 + exp
(
η
(1)
0 + η
(1)
1 T +A
>η(1)2
)
+ exp
(
η
(2)
0 + η
(2)
1 T +A
>η(2)2
) , (1.4)
where ρk = Pr(Dk = 1|T,A), k = 1, 2. Then, they jointly considered the verification model
(1.3) and the disease model (1.4) to construct the (observed) log-likelihood function, `(φ,η)
say, where η = (η
(1)
0 , η
(1)
1 ,η
(1)>
2 , η
(2)
0 , η
(2)
1 ,η
(2)>
2 )
> is the vector of parameters of the disease
model. The authors proved that the joint model based on (1.3) and (1.4) is identifiable. Then,
the maximum likelihood estimator (MLE) of (φ>,η>)> can be obtained by maximizing `(φ,η)
or solving the corresponding score equation. Based on imputation and re-weighting methods,
four estimators for each disease status can be obtained: FI, with D̂ki,FI = ρˆki = P̂r(Dk =
1|Ti,Ai); MSI, with D̂ki,MSI = ViDki+(1−Vi)ρˆk(0)i, where ρˆk(0)i = P̂r(Dki = 1|Ti,Ai, Vi = 0);
IPW, with D̂ki,IPW = ViDki/pˆii and PDR, with D̂ki,PDR = ViDki/pˆii − ρˆk(0)i(Vi − pˆii)/pˆii, with
pˆii = P̂r(Vi = 1|Ti,Ai, D1i, D2i). Therefore, bias-corrected VUS estimators are derived by
using quantities D̂ki,∗ in (1.2), i.e.,
µ̂∗ =
n∑
i=1
n∑
`=1,`6=i
n∑
r=1
r 6=`,r 6=i
Ii`rD̂1i,∗D̂2`,∗D̂3r,∗
n∑
i=1
n∑
`=1,`6=i
n∑
r=1
r 6=`,r 6=i
D̂1i,∗D̂2`,∗D̂3r,∗
. (1.5)
Here, the symbol ∗ stands for type of estimator, i.e., FI, MSI, IPW and PDR.
Despite its usefulness, the above reviewed approach presents some limitations. Firstly, it
is scarcely flexible, since identifiability is proven only for the specific parametric assumptions
about the verification and the disease processes. Secondly, because of NI missigness, it does
not allow a statistical check of appropriateness of such assumptions (see also Riddles et al.,
2016, Morikawa et al., 2017 and Yu et al., 2018). Finally, as pointed out by the authors
themselves, MLE of ignorable/nonignorable parameters λ1 and λ2 are typically highly biased,
in cases of moderate or even high sample sizes.
In the present paper, we try to overcome such limitations. More precisely, here we consider
the mean score function as a tool to estimate the parameters in the verification model, and
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avoid identifiability problems by resorting to the introduction of instrumental variables (Wang
et al., 2014; Riddles et al., 2016). As we show in what follows, in order to solve the mean
score equation derived by the chosen verification model, we preliminarily need to estimate
the parameters of a model for the disease process, but its specification is required only for
verified subjects. Thus, the new proposed approach essentially avoids the specification of
a parametric regression model for the disease status of the whole sample, and presents the
advantage that it allows a statistical evaluation, based on the available sample data, of the
adequacy of the required conditional (to V = 1) disease model. Furthermore, as confirmed
by our simulation experiments, the reduction in complexity of the adopted model translates
into a greater stability of estimates of the parameters.
Based on the new approach, we provide four new VUS estimators (FI, MSI, IPW and
PDR), which accommodate for nonignorable missingness of the disease status. We prove
consistency and asymptotic normality of the proposed estimators, and also provide estimators
of their variances.
The paper is organised as follows. In Section 2, we present the proposed approach, and
give the new bias–corrected VUS estimators, for which, in Section 3, we discuss the asymptotic
behaviour. In Section 4, we present the results of the simulation study, and in Section 5 we
give an illustrative application. Section 6 contains some final remarks. Some technical details
can be found in Appendix.
2 The proposal
It is worth noting that MLE of (φ>,η>)>, on which estimators (1.5) ultimately rely, could
be also obtained as solution of the so-called mean score equation (Louis, 1982; Kim and Shao,
2013; Riddles et al., 2016). Let S(φ) and S(η) denote the score functions derived from the
verification model (1.3) and from the disease model (1.4), respectively. For the joint model,
the mean score function is S¯(φ,η) = (S¯(φ), S¯(η))> (Kim and Shao, 2013), with
S¯(φ) =
n∑
i=1
[
Vih(φ;Vi, Ti,Ai, D1i, D2i) + (1− Vi)E0 {h(φ;Vi, Ti,Ai, D1, D2)|Ti,Ai}
]
S¯(η) =
n∑
i=1
[
Viu(η;Ti,Ai, D1i, D2i) + (1− Vi)E0 {u(η;Ti,Ai, D1, D2)|Ti,Ai}
]
, (2.1)
where h(φ; ·) and u(η; ·) denote the standard contributions to S(φ) and S(η), respectively.
Terms E0(·|Ti,Ai) = E(·|Ti,Ai, Vi = 0), represent the contribution to the scores, arising from
unverified subjects.
Hereafter, we consider an alternative estimation procedure which solves the mean score
equation derived from the verification model only, and uses instrumental variables. To this
aim, we assume that the vector of covariates A can be decomposed as A =
(
A>1 ,A>2
)>
such
that the verification status V does not depend on A2 given T , A1, D1 and D2. Variable A2
is known as instrumental variable and helps to make the verification model identifiable (see
Wang et al., 2014 and Riddles et al., 2016) without further assumptions on the disease model.
4
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By using the instrumental variable A2, we can reduce the verification model (1.3) to
pi = Pr(V = 1|T,A, D1, D2) = Pr(V = 1|T,A1, D1, D2),
=
exp
(
β0 + β1T + β
>
2,1A1 + λ1D1 + λ2D2
)
1 + exp
(
β0 + β1T + β
>
2,1A1 + λ1D1 + λ2D2
) = pi(T,A1, D1, D2;γ) (2.2)
where γ =
(
β0, β1,β
>
2,1, λ1, λ2
)>
. Then, MLE estimate of γ can be obtained by solving the
mean score equation S¯(γ) = 0 where
S¯(γ) =
n∑
i=1
[
Vih(γ;Vi, Ti,A1i, D1i, D2i) + (1− Vi)E0 {h(γ;Vi, Ti,A1i, D1, D2)|Ti,Ai}
]
(2.3)
with
h(γ;Vi, Ti,A1i, D1i, D2i) = Zi {Vi − pi(Ti,A1i, D1i, D2i;γ)}
for Zi = (1, Ti,A
>
1i, D1i, D2i)
> and
E0 {h(γ;Vi, Ti,A1i, D1i, D2i)|Ti,Ai}
= E {h(γ; 0, Ti,A1i, D1i, D2i)|Ti,Ai, Vi = 0}
= Pr(D1i = 1|Ti,Ai, Vi = 0)h(γ; 0, Ti,A1i, 1, 0) + Pr(D2i = 1|Ti,Ai, Vi = 0)h(γ; 0, Ti,A1i, 0, 1)
+ Pr(D3i = 1|Ti,Ai, Vi = 0)h(γ; 0, Ti,A1i, 0, 0). (2.4)
Let ρk(v) denote Pr(Dk = 1|V = v, T,A) for k = 1, 2, 3 and v = 0, 1. By an application of
Bayes’ rule (see Appendix A), it can be shown that
ρ1(0)(λ1, λ2) =
ρ1(1)e
λ2
ρ1(1)eλ2 + ρ2(1)eλ1 + ρ3(1)eλ1+λ2
,
ρ2(0)(λ1, λ2) =
ρ2(1)e
λ1
ρ1(1)eλ2 + ρ2(1)eλ1 + ρ3(1)eλ1+λ2
, (2.5)
ρ3(0)(λ1, λ2) =
ρ3(1)e
λ1+λ2
ρ1(1)eλ2 + ρ2(1)eλ1 + ρ3(1)eλ1+λ2
.
Hence, the mean score function (2.3) depends on the disease probabilities for verified units
only. If (just to keep the parallel with the proposal in To Duc et al. (2019)) we use a
multinomial logistic regression model for the conditional disease probabilities ρk(1) = Pr(Dk =
1|V = 1, T,A), i.e.,
ρk(1) ≡
exp
(
η
(k)
0 + η
(k)
1 T +A
>η(k)2
)
1 + exp
(
η
(1)
0 + η
(1)
1 T +A
>η(1)2
)
+ exp
(
η
(2)
0 + η
(2)
1 T +A
>η(2)2
) ,
= ρk(1)(η) (2.6)
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k = 1, 2, the functions ρk(0)(λ1, λ2) depend also on η, and the expressions in (2.5) become
ρ1(0)(η, λ1, λ2) =
ρ1(1)(η)e
λ2
ρ1(1)(η)eλ2 + ρ2(1)(η)eλ1 + ρ3(1)(η)eλ1+λ2
,
ρ2(0)(η, λ1, λ2) =
ρ2(1)(η)e
λ1
ρ1(1)(η)eλ2 + ρ2(1)(η)eλ1 + ρ3(1)(η)eλ1+λ2
, (2.7)
ρ3(0)(η, λ1, λ2) =
ρ3(1)(η)e
λ1+λ2
ρ1(1)(η)eλ2 + ρ2(1)(η)eλ1 + ρ3(1)(η)eλ1+λ2
.
By using (2.4) and (2.7), the mean score function (2.3) can be rewritten as
S¯(γ;η) =
n∑
i=1
si(γ;η)
=
n∑
i=1
[
Vih(γ; 1, Ti,A1i, D1i, D2i) + (1− Vi)
{
ρ1(0)i(η, λ1, λ2)h(γ; 0, Ti,A1i, 1, 0)
+ ρ2(0)i(η, λ1, λ2)h(γ; 0, Ti,A1i, 0, 1) + ρ3(0)i(η, λ1, λ2)h(γ; 0, Ti,A1i, 0, 0)
}]
.(2 8)
Then, once an estimate η̂ is available, we can get an empirical form of the mean score function
(2.3), say S¯(γ; η̂). The empirical mean score equation S¯(γ; η̂) = 0 can be solved to obtain an
estimate γ̂ of γ.
Observe that γ̂ would be the MLE estimate only if η̂ was solution of equation (2.1).
It should be noted, however, that in our simplified approach, η̂ is the solution of a score
equation that depends on the parametric model specification for the conditional (to V = 1)
disease process. The verification mechanism may be modelled by means of a generalised linear
regression model for binary data with a fixed link function (e.g., logistic, probit, log-log or
complementary log-log). Whichever choice is taken, identifiability of the model holds thanks
to the use of instrumental variables. In what follows, for the purposes of presentation, we
adopt a standard logistic model for the verification process, and a multinomial logistic model
for the conditional (to verification) disease process, a solution that also allow to keep the
parallel with the approach in To Duc et al. (2019).
Let U(η) =
n∑
i=1
Viui(η), with ui = u(η;Ti,Ai, D1i, D2i), denote the estimating function
for η based on the verified units in the sample. Since our empirical mean score equation
S¯(γ; η̂) = 0 is a specific case of a more general one discussed by Riddles et al. (2016), it
follows that, under certain regularity conditions given in Appendix B, γ̂ and η̂ are consistent
and asymptotically normal estimators (see Theorem 1 in Riddles et al., 2016).
In order to obtain four bias-corrected VUS estimators (FI, MSI, IPW and PDR), we follow
the arguments in To Duc et al. (2019), starting by the fact that
E
[
Viρk(1)i(η) + (1− Vi)ρk(0)i(η, λ1, λ2)|Ti,Ai
]
= Pr(Dk = 1|Ti,Ai)
and considering the quantities
Dki,FI(η, λ1, λ2) = Viρk(1)i(η) + (1− Vi)ρk(0)i(η, λ1, λ2),
6
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Dki,MSI(η, λ1, λ2) = ViDki + (1− Vi)ρk(0)i(η, λ1, λ2),
Dki,IPW(γ) =
ViDki
pii(γ)
and Dki,PDR(η,γ) =
ViDki
pii(γ)
− ρk(0)i(η, λ1, λ2)
Vi − pii(γ)
pii(γ)
.
in which we stressed the fact that the probabilities of selection for verification pii depend on γ.
Plugging in the above expressions the estimates η̂ and γ̂, yields the estimates D̂ki,FI, D̂ki,MSI,
D̂ki,IPW and D̂ki,PDR. Then, the bias-corrected VUS estimators are obtained by replacing
each disease status in (1.2) with the new estimates D̂ki,∗, where the symbol ∗ indicates, again,
the kind of estimator, i.e., FI, MSI, IPW and PDR.
Note that, the parameters γ of the verification model (2.2) and η of the conditional (to
V = 1) disease model (2.6) are estimated separately (see the estimation process in Appendix
C). However, the accuracy of the estimates pii in the verification model (2.2) may suffer
from possible fitting’s problems in the disease model (2.6), because the empirical mean score
equation uses η̂. On the other hand, the estimates ρ̂k(0)i also may be affected by possible poor
accuracy in the estimation of λ1, λ2 or η. Ultimately, the fact that the proposed method is a
parametric method has as a consequence that it could produce VUS estimates even strongly
influenced by incorrect specifications of the involved models.
3 Asymptotic behaviour
As for the estimators discussed in To Duc et al. (2019), the new proposed VUS estimators
can be found as solutions of appropriate estimating equations, solved along with the score
equations U(η) = 0 and the empirical mean score equation S¯(γ; η̂) = 0. The estimating
functions for FI, MSI, IPW and PDR estimators have generic term (corresponding to a generic
triplet of sample units), respectively,
Gi`r,FI(µ,η,γ) = D1i,FI(η, λ1, λ2)D2`,FI(η, λ1, λ2)D3r,FI(η, λ1, λ2) (Ii`r − µ) ,
Gi`r,MSI(µ,η,γ) = D1i,MSI(η, λ1, λ2)D2`,MSI(η, λ1, λ2)D3r,MSI(η, λ1, λ2) (Ii`r − µ) ,
Gi`r,IPW(µ,η,γ) = D1i,IPW(γ)D2`,IPW(γ)D3r,IPW(γ) (Ii`r − µ) ,
Gi`r,PDR(µ,η,γ) = D1i,PDR(η,γ)D2`,PDR(η,γ)D3r,PDR(η,γ) (Ii`r − µ) ,
for i 6= `, ` 6= r and r 6= i. In the following, we will use the general notation Gi`r,∗(µ,η,γ),
where ∗ stands for FI, MSI, IPW and PDR, and denote by µ˜∗ the corresponding new VUS
estimator. Moreover, let η0, γ0 and µ0 be the true parameter values. We assume that
(C1) the U–process,
√
n {G∗(µ,η,γ)− e∗(µ,η,γ)}, is stochastically equicontinuous, where
G∗(µ,η,γ) =
1
6n(n− 1)(n− 2)
n∑
i=1
n∑
`=1,` 6=i
n∑
r=1
r 6=`,r 6=i
{
Gi`r,∗(µ,η,γ) +Gir`,∗(µ,η,γ)
+G`ir,∗(µ,η,γ) +G`ri,∗(µ,η,γ) +Gri`,∗(µ,η,γ) +Gr`i,∗(µ,η,γ)
}
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and
e∗(µ,η,γ) =
1
6
E
{
Gi`r,∗(µ,η,γ) +Gir`,∗(µ,η,γ) +G`ir,∗(µ,η,γ) +G`ri,∗(µ,η,γ)
+Gri`,∗(µ,η,γ) +Gr`i,∗(µ,η,γ)
}
;
(C2) e∗(µ,η,γ) is differentiable in (µ,η,γ), and
∂e∗(µ,η0,γ0)
∂µ
∣∣∣∣∣
µ=µ0
6= 0;
(C3) G∗(µ,η,γ) and
∂G∗(µ,η,γ)
∂(η,γ)> converge uniformly (in probability) to e∗(µ,η,γ) and
∂e∗(µ,η,γ)
∂(η,γ)> ,
respectively.
Let Oi = (Ti,A
>
i , D1i, D2i, D3i, Vi)
>, Iη(η) = E
{
−∂ui(η)
∂η>
}
, Is,γ(η,γ) = E
{
−∂si(γ;η)
∂γ>
}
and Is,η(η,γ) = E
{
−∂si(γ;η)
∂η>
}
.
Theorem 3.1. Suppose that conditions (C1)–(C3), and (D1)–(D9) in Appendix B, hold.
Then, under the verification model (2.2) and the (conditional) disease model (2.6), µ˜∗ is
consistent and asymptotically normal, i.e.,
√
n (µ˜∗ − µ0) d−→ N (0, σ2∗),
where σ2∗ =
Var {Λi,∗ +Qi,∗}
[Pr(D1 = 1) Pr(D2 = 1) Pr(D3 = 1)]
2 and
Λi,∗ =
1
2
E
{
Gi`r,∗(µ0,η0,γ0) +Gir`,∗(µ0,η0,γ0) +G`ir,∗(µ0,η0,γ0)
+G`ri,∗(µ0,η0,γ0) +Gri`,∗(µ0,η0,γ0) +Gr`i,∗(µ0,η0,γ0)
∣∣Oi},
Qi,∗ =
∂e∗(µ0,η,γ)
∂(η,γ)>
∣∣∣∣
(η,γ)>=(η0,γ0)>
( Iη(η0) 0
Is,η(η0,γ0) Is,γ(η0,γ0)
)−1(
Viui(η0)
si(γ0;η0)
)
.
Proof. (sketch). Under the verification model (2.2) and the disease model (2.6), we can show
that quantities Gi`r,∗(µ0,η0,γ0) have 0 expectation. Then, the consistency of µ˜∗ can be
proven by arguments similar to those used in Theorem 1 of To Duc et al. (2019). As for the
asymptotic normality, we follow the steps in the proof of Theorem 2 in To Duc et al. (2019).
In particular, using also equation (B.1), since e∗(µ0,η0,γ0) = 0, we can write
0 =
∂e∗(µ,η0,γ0)
∂µ
∣∣∣∣
µ=µ0
√
n(µ˜∗ − µ0) +
√
nG∗(µ0,η0,γ0)
+
∂e∗(µ0,η,γ)
∂(η,γ)>
∣∣∣∣
(η,γ)>=(η0,γ0)>
√
n
(
η̂ − η0
γ̂ − γ0
)
+ op(1). (3.1)
An application of a standard result about the limit distribution of U-statistics (van der Vaart,
2000), yields to
√
nG∗(µ0,η0,γ0)
d−→ 1√
n
n∑
i=1
Λi,∗ .
8
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This, together with the fact that
∂e∗(µ,η0,γ0)
∂µ
∣∣∣∣
µ=µ0
= −Pr(D1 = 1) Pr(D2 = 1) Pr(D3 = 1),
and equation (B.1), show that (3.1) is equivalent to
Pr(D1 = 1) Pr(D2 = 1) Pr(D3 = 1)
√
n(µ˜∗ − µ0)
=
∂e∗(µ0,η,γ)
∂(η,γ)>
∣∣∣∣
(η,γ)>=(η0,γ0)>
( Iη(η0) 0
Is,η(η0,γ0) Is,γ(η0,γ0)
)−1
1√
n
n∑
i=1
(
Viui(η0)
si(γ0;η0)
)
+
1√
n
n∑
i=1
Λi,∗ + op(1).
Then, we have that
√
n(µ˜∗ − µ0) = 1√
n
n∑
i=1
Λi,∗ +Qi,∗
Pr(D1 = 1) Pr(D2 = 1) Pr(D3 = 1)
+ op(1),
and the asymptotic normality of µ˜∗ follows by the Central Limit Theorem.
The asymptotic variances σ2∗ can be consistently estimated by
σˆ2∗ =
1
n− 1
n∑
i=1
{(
Λˆi,∗ + Q̂i,∗
)
− (Λ∗ +Q∗)}2
×
{
P̂r∗(D1 = 1)P̂r∗(D2 = 1)P̂r∗(D3 = 1)
}−2
, (3.2)
where
Λˆi,∗ =
1
(n− 1)(n− 2)
n∑
`=1
`6=i
n∑
r=1
r 6=`,r 6=i
{
Gi`r,∗(µ̂∗, η̂, γ̂) +G`ir,∗(µ̂∗, η̂, γ̂)
+Gr`i,∗(µ̂∗, η̂, γ̂)
}
Q̂i,∗ =
1
(n− 1)(n− 2)
n∑
i=1
n∑
`=i
`6=i
n∑
r=1
r 6=`,r 6=i
∂Gi`r,∗(µ̂∗,η,γ)
∂(η,γ)>
∣∣∣∣
(η,γ)>=(η̂,γ̂)>
×

n∑
i=1
∂
∂η>Viui(η̂) 0
n∑
i=1
∂
∂η> si(γ̂; η̂)
n∑
i=1
∂
∂γ> si(γ̂; η̂)

−1(
Viui(η̂)
si(γ̂; η̂)
)
and
P̂r∗(Dk = 1) =
1
n
n∑
i=1
D̂ki,∗, Λ∗ =
1
n
n∑
i=1
Λˆi,∗, Q∗ =
1
n
n∑
i=1
Q̂i,∗.
Clearly, alternative approaches to estimate the variance of the proposed VUS estimators
are possible. For instance, one may resort to the classical bootstrap method.
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4 Simulation study
In order to compare the proposed mean score equation-based approach with the fully likelihood-
based method in (To Duc et al., 2019) and to evaluate the performance of the new bias-
corrected VUS estimators, we carry out several simulation experiments. The number of
replications is 1000 in each experiment, and the considered sample sizes are 150, 250, 500 and
1000.
4.1 Simulation setup
With regard to data generation, we consider the following six different scenarios:
I. For each unit, the test result T and a covariate A are generated by the model
(T,A) ∼ N
((
3.7
1.85
)
,
(
3.71 1.36
1.36 3.13
))
.
The disease status D = (D1, D2, D3)> is generated by the following multinomial logistic
model:
log
(
Pr(D1 = 1|T,A)
Pr(D3 = 1|T,A)
)
= 15− 3.3T − 0.7A,
log
(
Pr(D2 = 1|T,A)
Pr(D3 = 1|T,A)
)
= 9.5− 1.7T − 0.3A.
The verification status V is simulated by the following logistic model
Pr(V = 1|T,A,D1, D2) = exp(2 + 0.5T − 1.2A− 2D1 −D2)
1 + exp(2 + 0.5T − 1.2A− 2D1 −D2) .
Under this setting, the verification rate is roughly 0.57 and the true VUS is 0.791. This
setting is the same as Scenario I in To Duc et al. (2019).
II. For each unit, the disease status D = (D1, D2, D3)> is generated from a multinomial
distribution with θ1 = 0.7, θ2 = 0.2 and θ3 = 0.1 (recall that θk = Pr(Dk = 1), k =
1, 2, 3). The test results T and a covariate A are generated as T |Dk = 1 ∼ N (k−1, 0.52)
and A|Dk = 1 ∼ N (0.5(k−1), 0.52), while the verification status V is simulated through
the model
Pr(V = 1|T,D1, D2) = exp(1 + T − 2D1 −D2)
1 + exp(1 + T − 2D1 −D2) .
The verification rate is roughly 0.44 and the true VUS is 0.843.
III. The disease status D is generated as in scenario I. The test results T and a covariate A1
are generated as T |Dk = 1 ∼ N (0.4(k − 1), 0.52) and A1|Dk = 1 ∼ N (0.5(k − 1), 0.52),
for k = 1, 2, 3. A second covariate A2 is simulated as A2|D1 = 1 ∼ U(−2,−1), A2|D2 =
1 ∼ U(−1, 1) and A2|D3 = 1 ∼ U(1, 2). The true VUS is 0.457. The verification status
V is simulated by a probit model
Pr(V = 1|T,A1, D1, D2) = Φ(1.5 + T − 0.5A1 − 2D1 −D2),
10
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where Φ(·) denotes cumulative distribution function of a standard normal. In this case,
the verification rate is roughly 0.47.
IV. The disease status D, the test result T and a covariate A are generated in the same way
as in scenario II. The verification status V is simulated through the model
Pr(V = 1|T,A,D1, D2) = exp(1 + T − 0.5A− 2D1 −D2)
1 + exp(1 + T − 0.5A− 2D1 −D2) .
The verification rate is roughly 0.42, and the true VUS still is 0.843.
V. We generate the test result T ∼ U(−3, 3), two covariates A1 ∼ N (0, 1) and A2 ∼
Ber(0.6). The disease status D = (D1, D2, D3)> is generated by using the multinomial
logistic model
log
(
Pr(D1 = 1|T,A1, A2)
Pr(D3 = 1|T,A1, A2)
)
= 5− 6T + 2A1 +A2,
log
(
Pr(D2 = 1|T,A1, A2)
Pr(D3 = 1|T,A1, A2)
)
= 4− 3T + 4A1 + 2A2.
The verification status V is simulated by the following model:
log
(
Pr(V = 1|T,A1, D1, D2)
Pr(V = 0|T,A1, D1, D2)
)
= 1 + 1.5T −A1 + 2A2 − 1.5D1 − 2D2.
In this scenario, the verification rate is roughly 0.56. The true VUS value is 0.74.
VI. We generate the test result T , and two covariates A1, A2 as in scenario IV. The disease
status D = (D1, D2, D3)> is generated by using the multinomial logistic model
log
(
Pr(D1 = 1|T,A1, A2)
Pr(D3 = 1|T,A1, A2)
)
= 5− 6T + 2A1 +A2 +A1A2,
log
(
Pr(D2 = 1|T,A1, A2)
Pr(D3 = 1|T,A1, A2)
)
= 4− 3T + 4A1 + 2A2 + 0.5A1A2.
The verification status V is simulated by the following model:
log
(
Pr(V = 1|T,A1, D1, D2)
Pr(V = 0|T,A1, D1, D2)
)
= 1 + 2T − 1.5A1 −D1 − 2D2.
The verification rate is roughly 0.46, and the true VUS value is 0.728.
Scenarios I and II aim to compare the discussed mean score equation-based approach with
the fully likelihood-based one, in terms of accuracy of parameter estimators in the verification
model, and VUS estimators. As pointed out above, scenario I is identical to Scenario I
in To Duc et al. (2019) and does not involve instrumental variables. On the contrary, in
scenario II the covariate A plays the role of instrumental variable. Moreover, scenarios II to
VI aim to assess the finite-sample behavior of new proposed bias-corrected VUS estimators.
In particular, as explained below, scenarios IV, V and VI serve to evaluate the effects on the
estimators of some types of misspecifications in the working models.
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By applying the Bayes’ rule, for all considered scenarios, the true conditional (to V = 1)
disease process takes the following form:
log
(
Pr(D1 = 1|T,A, V = 1)
Pr(D3 = 1|T,A, V = 1)
)
= log
(
pi10
pi00
)
+ log
(
Pr(D1 = 1|T,A)
Pr(D3 = 1|T,A)
)
,
log
(
Pr(D2 = 1|T,A, V = 1)
Pr(D3 = 1|T,A, V = 1)
)
= log
(
pi01
pi00
)
+ log
(
Pr(D2 = 1|T,A)
Pr(D3 = 1|T,A)
)
,
where A is simply the covariate A in the scenarios I, II, IV and V, A = (A1, A2)
> in scenarios
III and VI and pi10, pi01 and pi00 denote Pr(V = 1|T,A, D1 = 1, D2 = 0), Pr(V = 1|T,A, D1 =
0, D2 = 1) and Pr(V = 1|T,A, D1 = 0, D2 = 0), respectively. Clearly, in practice this is a
multinomial logistic model with unknown offset terms (intercepts).
In making simulations, when considering the new mean score equation-based approach, we
fit the the conditional disease model as a multinomial logistic one, i.e., we specify the working
conditional disease model as follows:
log
(
Pr(D1 = 1|T,A, V = 1)
Pr(D3 = 1|T,A, V = 1)
)
= η
(1)
0 + η
(1)
1 T +A
>η(1)2 ,
log
(
Pr(D2 = 1|T,A, V = 1)
Pr(D3 = 1|T,A, V = 1)
)
= η
(2)
0 + η
(2)
1 T +A
>η(2)2 ,
where A = A for scenarios I, II and IV, A = (A1, A2)
> for scenarios III and V and A =
(A21, A2)
> for scenario VI. As for the verification model, in the estimation procedure we
use the correct logistic model in scenarios I, II, III and VI, while in scenarios IV we use a
logistic models involving only T , and in scenario V we use a probit model involving only T
and the covariate A1. Therefore, the working models are correctly specified in scenarios I,
II and III, while they present various types of misspecification in scenarios IV, V and VI.
More precisely: in scenario IV, we omit the covariate A in the verification model and use it
as instrumental variable; in scenario V, we omit the covariate A2 in the verification model,
use it as instrumental variable and incorrectly define the model (probit instead of logit); in
scenario VI, we use A21 instead of A1 and omit the interaction term in the conditional disease
model. Finally, as for the fully likelihood-based approach, in scenarios I and II, the working
(unconditional) disease model and the working verification model are both correctly specified.
4.2 Computational aspects
In order to obtain the new VUS estimates, in our simulation we need to solve, at each replica-
tion, the score equation U(η) = 0, and then the empirical mean score equation S¯(γ; η̂) = 0.
The first equation refers to the conditional (to V = 1) disease model and, since we work with a
multinomial logistic model in all scenarios, we resort to the routine multinom() (of R package
nnet) to solve it. Given η̂, the empirical mean score equation S¯(γ; η̂) = 0 could be solved
in γ by using some numeric algorithm, such the ones deployed in the R routine nleqslv().
However, numerical algorithms for solving equations are often poorly stable and reliable, or,
better, are less reliable than optimization algorithms. Therefore, in order to obtain γ̂, we min-
imize the squared Euclidean norm of S¯(γ; η̂), i.e.,
∥∥S¯(γ; η̂)∥∥2. The optimization is performed
by using the L-BFGS-B algorithm supplied in the R routine optim().
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4.3 Results
Simulation results are given in tables 1-3. Table 1 refers to the comparison between the mean
score equation-based approach (MSEq) and the fully likelihood-based approach (logLike). For
three different sample sizes, i.e., 150, 250 and 500, the table provides Monte Carlo means for
the estimators of the parameters in the verification model, together with Monte Carlo means
for the four (FI, MSI, IPW and PDR) VUS estimators, for scenarios I and II. Recall that,
in such scenarios, the considered working models are correctly specified. The results clearly
show that the new approach achieves better performance, providing less biased estimators,
already at the smallest sample size.
Table 1 – Monte Carlo means for the estimators of the parameters in the verifi-
cation model and for the corresponding four bias–corrected VUS estimators. The
true values are: for scenario I, β0 = 2, β1 = 0.5, β2 = −1.2, λ1 = −2, λ2 = −1
and VUS = 0.791; for scenario II, β0 = 1, β1 = 1, λ1 = −2, λ2 = −1 and VUS
= 0.843.
n = 150 n = 250 n = 500
MSEq logLike MSEq logLike MSEq logLike
Scenario I
β̂0 2.081 0.750 1.992 1.189 2.274 1.806
β̂1 0.595 0.782 0.550 0.658 0.491 0.546
β̂2 −1.281 −1.271 −1.255 −1.236 −1.230 −1.217
λ̂1 −1.870 −0.127 −1.919 −0.943 −2.192 −1.763
λ̂2 −0.132 −0.122 −0.341 −0.435 −0.902 −0.867
FI 0.775 0.761 0.776 0.771 0.784 0.783
MSI 0.772 0.757 0.774 0.769 0.783 0.783
IPW 0.778 0.765 0.776 0.770 0.783 0.782
PDR 0.773 0.757 0.773 0.765 0.781 0.782
Scenario II
β̂0 3.154 5.071 2.119 5.217 1.553 4.011
β̂1 1.108 1.870 1.078 1.452 1.039 1.154
λ̂1 −4.131 −5.173 −3.115 −5.721 −2.549 −4.895
λ̂2 −0.580 −4.365 −0.899 −4.757 −1.274 −3.913
FI 0.844 0.799 0.845 0.822 0.843 0.835
MSI 0.841 0.795 0.843 0.820 0.841 0.833
IPW 0.841 0.822 0.842 0.829 0.841 0.836
PDR 0.839 0.801 0.842 0.825 0.841 0.835
Results in Table 2 allow us to evaluate the behavior of the proposed VUS estimators, and
of the corresponding variance estimators based on (3.2), when the considered working models
are correctly specified. For both scenarios II and III and four different sample sizes (150,
250, 500 and 1000), the table contains Monte Carlo relative biases, Monte Carlo standard
deviations and (means of) estimated standard deviations based on (3.2), for the new VUS
estimators. The table also provides the empirical coverages of the 95% confidence intervals
for the VUS, obtained through the normal approximation approach applied to each estimator
and the use of the corresponding variance estimator (3.2).
Overall, Table 2 shows that the proposed approach provides satisfactory results in terms
of relative bias and coverage probability when the verification models are correctly specified.
At the smallest sample size, the larger absolute relative bias is equal to 1.4% (scenario III). As
expected, when the sample size increases, the relative bias of the VUS estimators decreases,
becoming negligible for n ≥ 250. Moreover, especially for scenario III (in which the verification
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process follows a probit model), in case of smallest sample size, n = 150, the (means of)
estimated standard deviations based on (3.2) still seem to be affected by a poor accuracy in
the estimation of the parameters in the working models. However, in similar cases, as shown
in the table, more accurate estimates of standard deviations can be obtained via bootstrap.
Bootstrap estimates also improve empirical coverage probabilities of confidence intervals, when
used within the normal approximation approach (see also the results for scenario II).
We emphasize that, when working models are correctly specified, low-accuracy problems
can be related to low verification rates. For example, in scenario III the verification rate is
0.47. If we change the verification process and use the following model to simulate Vi values:
Pr(V = 1|T,A1, D1, D2) = Φ(2.5 + T − 1.2A1 − 2D1 −D2),
the verification rate becomes roughly 0.72, and the corresponding simulation results (for
n = 150 and 1000 replications), given below, are clearly better than those in Table 2.
Bias(%) MCSD ASD CP.Asy(%)
FI −0.6 0.070 0.075 95.8
MSI −0.6 0.070 0.075 95.8
IPW 0.1 0.074 0.069 93.2
PDR −0.6 0.070 0.075 95.8
Table 3 presents the simulation results for scenarios IV-VI, in which the working models
are, in various ways, misspecified. Again, for each scenario and four different sample sizes,
the table gives Monte Carlo relative bias, Monte Carlo standard deviations and (means of)
estimated standard deviations based on (3.2), for the new VUS estimators. The table also
provides the empirical coverages of the 95% confidence intervals for the VUS, obtained through
the normal approximation approach applied to each estimator and the use of the corresponding
variance estimator (3.2).
In the considered scenarios, all proposed VUS estimators appear to be biased, even when
the sample size increases. However, simulation results appear to stay on acceptable levels (the
relative biases are not too large and the coverage probabilities are close to 95%) in scenarios
IV and V, i.e., when the misspecification follows by the omission of a variable and/or a
wrong choice of the link function in the working generalized linear model for the verification
process. Clearly, due to the strong deviation between the working conditional disease model
and the true one, the results are significantly worse in the scenario VI. Anyway, variance
estimators (3.2) seem relatively more robust with respect to the considered misspecifications
in the working models.
5 Application
We illustrate an application of our method by using data from the Pre-PLCO Phase II
Dataset, from the SPORE/Early Detection Network/Prostate, Lung, Colon, and Ovarian
Cancer Study. The study protocol and the data are publicly available at the address 1. In
1http://edrn.nci.nih.gov/protocols/119-spore-edrn-pre-plco-ovarian-phase-ii-validation
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this study, several serum protein biomarkers are evaluated in terms of their ability to cor-
rectly classify possible epithelial ovarian cancer (EOC) cases into benign disease, early stage
(I-II) and late stage (III-IV). Among such biomarkers, we are interested in insulin-like growth
factor-II (IGF-II), previously studied in Mor et al. (2005) and Visintin et al. (2008) to distin-
guish non-diseased from cancer cases (early stage and the late stage). The data we consider
refer to 156 patients with benign disease, 71 patients with early stage, and 82 with late stage.
Moreover, the data present 87 unverified units; therefore, only 78% of patients receive the
assessment of their true disease status.
Verified − Benign disease Verified − Early stage Verified − Late stage
0
10
00
20
00
30
00
IG
F−
II
Figure 1 – Boxplot for the IGF-II values, stratified by the disease status (verified
units only).
The boxplots for the IGF-II values, stratified by the disease status and based on the
verified units only, are presented in Figure 1, which show that lower values of IGF-II are
associated with higher severity of disease; thus, in our analysis, we consider minus the values
of the IGF-II as test values. Moreover, we consider two other serum proteins, i.e., HE4 and
CA125, as covariates.
Our goal is to estimate the VUS for the IGF-II biomarker. In the analysis, we standardize
the values of IGF-II, HE4 and CA125, and below, for convenience, denote them as T , A1 and
A2, respectively. We also let D1 and D2 to be the variables corresponding to benign disease
and early stage, respectively.
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We fit the conditional (to V = 1) disease model by using a multinomial logistic regression
model with T , A1 and A2 as predictors and late stage as reference level. As for the verification
model, we consider a logistic model and a probit model, with only T as a predictor; hence,
A1 and A2 are used as instrumental variables. The estimated parameters, estimated standard
errors and corresponding p-values for the significance test for coefficients in the models are
given in Table 4. The p-values refer to the Wald-type statistics, which use results in (B.4).
The resulting p-values for ignorable/nonignorable coefficients in both models (logistic and
probit), indicate that, in such case, the missing data mechanism is nonignorable.
Table 4 – Application to IGF-II biomarker: estimated coefficients (Est.), standard
errors (SE) and corresponding p-values for (conditional) disease and verification
models; VUS estimates, along with related standard errors and 95% confidence
intervals.
Disease model
Benign disease Early stage
Est. SE p-value Est. SE p-value
Intercept −1.832 0.786 0.020 0.528 0.218 0.015
T −0.922 0.204 < 0.001 −0.880 0.205 < 0.001
A1 −1.289 0.444 0.004 −0.625 0.168 < 0.001
A2 −17.131 4.325 < 0.001 −0.026 0.141 0.852
Verification model
Logit link Probit link
Est. SE p-value Est. SE p-value
Intercept 6.186 1.455 <0.001 2.966 0.621 <0.001
T −1.338 0.376 <0.001 −0.659 0.162 <0.001
D1 −5.733 1.501 <0.001 −2.649 0.639 <0.001
D2 4.207 0.961 <0.001 1.899 0.631 0.003
bias–corrected VUS
Logit link Probit link
Est. SE 95% CI Est. SE 95% CI
FI 0.317 0.025 (0.268, 0.366) 0.317 0.025 (0.268, 0.366)
MSI 0.343 0.028 (0.287, 0.398) 0.343 0.028 (0.287, 0.398)
IPW 0.243 0.087 (0.073, 0.413) 0.299 0.056 (0.188, 0.410)
PDR 0.342 0.027 (0.289, 0.395) 0.341 0.030 (0.283, 0.399)
Table 4 also provides the four bias-corrected VUS estimates, along with the standard er-
rors and 95% confidence intervals (CI), constructed using normal approximation and (3.2).
The Na¨ıve VUS estimate, calculated from verified subjects only, is 0.460 with standard error
0.035 and 95% CI (0.393, 0.528). Therefore, all bias-corrected VUS estimates are significantly
different to the Na¨ıve one. Moreover, unlike the logistic model, the IPW estimate in probit
model is comparable to the other VUS estimates. This may suggest that the probit link func-
tion is a good choice for the generalized regression model describing the verification process
for these data.
Finally, we highlight the purely illustrative nature of this application and the fact that, in
real applications, the approach proposed in this paper allows to evaluate the model chosen to
describe the (conditional) disease process by diagnostic procedures and/or ad hoc statistical
tests present in the litterature, as those, for instance, in Goeman and le Cessie (2006) for the
18
Improving VUS estimation when data are missing not at random
multinomial logistic regression model.
6 Conclusion
In this paper, we propose a mean score equation-based approach to estimate the volume
under a ROC surface when the disease status is missing not at random. This approach can
take advantage of the use of instrumental variables, which help avoid possible identifiability
problems. We prove that our proposed bias–corrected VUS estimators are consistent and
asymptotically normal.
Our method is essentially a parametric method, and requires the estimation of the param-
eters of a (parametric) model chosen to describe the conditional (to V = 1) disease process,
and then the solution of an empirical mean score equation resulting from a parametric model
chosen for the verification process. The method may also be used in a semiparametric context,
by resorting to a nonparametric regression approach to fit the conditional disease model, as
in Morikawa et al. (2017). Clearly, this topic deserves further investigation.
Compared to the fully likelihood-based approach discussed in To Duc et al. (2019), the
new method is simpler, and more flexible also thanks to the possible use of instrumental
variables. Moreover, as our simulation results show, the new bias–corrected VUS estimators
are generally more accurate with moderate sample sizes.
Resorting to instrumental variables may be necessary when relying on working models
other than those, namely logistic and multinomial logistic, assumed by To Duc et al. (2019)
to describe, respectively, the verification and disease process. In practice, however, the choice
of variables that could play the role of instrumental variables is not trivial. With respect to
this issue, we suggest a possible selection strategy that foresees three steps:
(i) choose a working model for the conditional (to V = 1) disease process and select (by
using a standard backward stepwise regression) a vector of covariates A, statistically
significant;
(ii) choose a working model for the verification process and, given the estimate η̂ obtained
in step (i), use, one at a time, the elements of A, jointly with the test T , to solve the
resulting empirical mean score equation S¯(γ; η̂) = 0;
(iii) take as vector of instrumental variables, the vector A2 consisting of the elements of A
resulting statistically non-significant at the previous step (ii).
Then, the final estimate γ̂ is obtained by solving the empirical mean score equation based on
T and, when A2 does not coincide with A, the component A1 of A =
(
A>1 ,A>2
)>
. This is
also the selection strategy that we used in the illustrative application of Section 5.
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A Conditional probabilities of disease for unverified subjects
Applying Bayes’ rule, we have
Pr(Dk = 1|V = v, T,A) = Pr(V = v|T,A1, Dk = 1) Pr(Dk = 1|T,A)
Pr(V = v|T,A)
for v = 0, 1. Thus, we obtain the following ratios
Pr(D1 = 1|V = 1, T,A)
Pr(D1 = 1|V = 0, T,A)
/
Pr(D3 = 1|V = 1, T,A)
Pr(D3 = 1|V = 0, T,A) =
Odd(T,A1, 1, 0;γ)
Odd(T,A1, 0, 0;γ)
,
Pr(D2 = 1|V = 1, T,A)
Pr(D2 = 1|V = 0, T,A)
/
Pr(D3 = 1|V = 1, T,A)
Pr(D3 = 1|V = 0, T,A) =
Odd(T,A1, 0, 1;γ)
Odd(T,A1, 0, 0;γ)
,
where
Odd(T,A1, d1, d2;γ) =
pi(T,A1, d1, d2;γ)
1− pi(T,A1, d1, d2;γ)
with (d1, d2) ∈ {(1, 0), (0, 1), (0, 0)}. These expressions are equivalent to the system of equa-
tions
ρ1(1)
ρ3(1)
=
ρ1(0)
ρ3(0)
Odd(T,A1, 1, 0;γ)
Odd(T,A1, 0, 0;γ)
, (A.1a)
ρ2(1)
ρ3(1)
=
ρ2(0)
ρ3(0)
Odd(T,A1, 0, 1;γ)
Odd(T,A1, 0, 0;γ)
. (A.1b)
By using the fact that ρ3(0) = 1− ρ1(0) − ρ2(0), from (A.1a), we obtain
ρ1(0) =
ρ1(1)(1− ρ2(0))
ρ3(1)
Odd(T,A1,1,0;γ)
Odd(T,A1,0,0;γ)
+ ρ1(0)
(A.2)
Substituting (A.2) into (A.1b), leads to the following equation
ρ2(1)
ρ3(1)
=
ρ2(0)
1− ρ1(1)(1−ρ2(0))
ρ3(1)
Odd(T,A1,1,0;γ)
Odd(T,A1,0,0;γ)
+ρ1(0)
− ρ2(0)
Odd(T,A1, 0, 1;γ)
Odd(T,A1, 0, 0;γ)
.
After some algebra, we obtain that ρ2(0) is equal to
ρ2(1)
Odd(T,A1,1,0;γ)
Odd(T,A1,0,0;γ)
ρ1(1)
Odd(T,A1,0,1;γ)
Odd(T,A1,0,0;γ)
+ ρ2(1)
Odd(T,A1,1,0;γ)
Odd(T,A1,0,0;γ)
+ ρ3(1)
Odd(T,A1,1,0;γ)
Odd(T,A1,0,0;γ)
Odd(T,A1,0,1;γ)
Odd(T,A1,0,0;γ)
,
and then ρ1(0) is
ρ1(1)
Odd(T,A1,0,1;γ)
Odd(T,A1,0,0;γ)
ρ1(1)
Odd(T,A1,0,1;γ)
Odd(T,A1,0,0;γ)
+ ρ2(1)
Odd(T,A1,1,0;γ)
Odd(T,A1,0,0;γ)
+ ρ3(1)
Odd(T,A1,1,0;γ)
Odd(T,A1,0,0;γ)
Odd(T,A1,0,1;γ)
Odd(T,A1,0,0;γ)
In case of the logistic model (2.2), it is straightforward to show that
Odd(T,A1, 1, 0;γ)
Odd(T,A1, 0, 0;γ)
= exp(λ1),
Odd(T,A1, 0, 1;γ)
Odd(T,A1, 0, 0;γ)
= exp(λ2).
Thus, we get the results in (2.5).
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B Conditions for asymptotic normality of
(
η̂>, γ̂>
)>
Recall that Iη(η) = E
{
−∂ui(η)
∂η>
}
, Is,γ(η,γ) = E
{
−∂si(γ;η)
∂γ>
}
, Is,η(η,γ) = E
{
−∂si(γ;η)
∂η>
}
and
consider the conditions:
(D1) Pr
(
Dk = 1|T,A1,A2 = a(1)2
)
6= Pr
(
Dk = 1|T,A1,A2 = a(2)2
)
for given two values a
(1)
2 6=
a
(2)
2 of the (instrumental) variable A2, and
Pr(V = 1|T,A, D1, D2) = Pr(V = 1|T,A1, D1, D2) = pi(T,A1, D1, D2;γ0)
with A =
(
A>1 ,A>2
)>
;
(D2) pi(Ti,A1i, D1i, D2i;γ) is a continuous function of γ with first and second derivatives
continuous in an open set containing γ0 as an interior point;
(D3) the variables (Ti,A
>
i , D1i, D2i, D3i, Vi)
>, i = 1, . . . , n, are independent and identically
distributed;
(D4) the parameter spaces Θ for η and Ω for γ are compact and have finite dimension;
(D5) pi(Ti,A1i, D1i, D2i;γ) is bounded away from 0.
(D6) the MLE , γ̂n say, is consistent and asymptotically normal;
(D7) E {U(η)} = 0 has a unique solution η0 ∈ Θ;
(D8) Iη(η0) exists and is invertible;
(D9) there exists a neighborhoodN of η0 such that the quantiles supη∈N ‖U(η)‖, supη∈N ‖ ∂∂η>U(η)‖
and supη∈N ‖U(η)U(η)>‖ have finite expectations, with ‖X‖ ≡
∑
i
∑
j X
2
ij .
By Theorem 1 in Riddles et al. (2016), under the regularity conditions (D1)–(D9), the solution(
η̂>, γ̂>
)>
of (
U(η)
S¯(γ;η)
)
=
(
0
0
)
is a consistent estimator of
(
η>0 ,γ>0
)>
, and satisfies
√
n
(
η̂ − η0
γ̂ − γ0
)
=
( Iη(η0) 0
Is,η(η0,γ0) Is,γ(η0,γ0)
)−1
1√
n
n∑
i=1
(
Viui(η0)
si(γ0;η0)
)
+ op(1). (B.1)
Thus, by the Central Limit Theorem,
(
η̂>, γ̂>
)>
is asymptotically normal. Moreover,
√
n (γ̂ − γ0) d−→ N (0,Σγ) , (B.2)
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where
Σγ = I−1s,γ(η0,γ0)Cov
{
si(γ0;η0)− Is,η(η0,γ0)I−1η (η0)ui(η0)
} I−1s,γ(η0,γ0)
and
√
n (η̂ − η0) d−→ N (0,Ση) , (B.3)
where Ση = I−1η (η0)Cov(ui(η0))I−1η (η0). Consistent estimators Σ̂γ of Σγ and Σ̂η of Ση can
be obtained by
Σ̂η = n
{
n∑
i=1
∂
∂η>
Viui(η̂)
}−1{ n∑
i=1
Viui(η̂)ui(η̂)
>
}{
n∑
i=1
∂
∂η>
Viui(η̂)
}−>
,
Σ̂γ = n
{
n∑
i=1
∂
∂γ>
si(γ̂; η̂)
}−1{ n∑
i=1
fi(η̂, γ̂)fi(η̂, γ̂)
>
}{
n∑
i=1
∂
∂γ>
si(γ̂; η̂)
}−>
, (B.4)
with fi(η̂, γ̂) = si(γ̂; η̂)−
{∑n
i=1
∂
∂η> si(γ̂; η̂)
}{∑n
i=1
∂
∂η>Viui(η̂)
}−1
Viui(η̂).
C Estimation Procedure
Modelling Verification Process
Modelling Disease Process for
Verified Subjects (eventually
using instrumental veriables)
η̂ ρk(0)i(η̂, λ1, λ2)
Empirical Mean
Score Equation
β̂0, β̂1,
β̂2,1, λ̂1, λ̂2
ρk(1)i(η̂)
ρk(0)i(η̂, λ̂1, λ̂2) pii
VUS-FI
Estimator
VUS-MSI
Estimator
VUS-PDR
Estimator
VUS-IPW
Estimator
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